openPR Logo
Press release

Myasthenia Gravis Therapeutics Analysis Alexion Pharmaceuticals, Inc., CSL Behring, Novartis

12-04-2018 10:36 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

Myasthenia Gravis Therapeutics Analysis Alexion

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development.

Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Download report sample at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/report-sample

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Browse report at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myasthenia-gravis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myasthenia Gravis Therapeutics Analysis Alexion Pharmaceuticals, Inc., CSL Behring, Novartis here

News-ID: 1417245 • Views:

More Releases from P&S Intelligence

Remote Access Provided by Cloud Category Fuels Call Center AI Market
Remote Access Provided by Cloud Category Fuels Call Center AI Market
In 2021, the call center AI market generated sales worth $1,982.9 million, and it is expected to contribute $12,910.6 million in 2030, progressing at a rate of 23.1% from 2021 to 2030, ascribed to the growing up requirements for improved data analytics to manage customer inquiries with the real-time response to improve customer engagement through social media. In order to pace up the 4th industrial revolution, businesses across various industries
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Market
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Marke …
The total value of the customer engagement solutions market was $18,186.8 million in 2021, and it will rise at a growth rate of above 10% in the near future, to reach $43,398.9 million by 2030. The major reasons behind the growth of this industry are growing usage of such solutions in serval industries like healthcare, telecommunications, BFSI and FMCG. North America will grow the fastest with a rate of 10.5% in
Reduced Operational Cost of Energy Efficient Motors Propels Motion Control Market
Reduced Operational Cost of Energy Efficient Motors Propels Motion Control Marke …
The motion control market generated a revenue of $14,887.5 million in 2021, and it is expected to contribute $23,286.4 million in 2030, progressing at a rate of 5.1% from 2021 to 2030, ascribed to the rising demand for industrial robots and integration of components with the motion control systems for convenient use. Moreover, the evolving motion control standards and protocols propel the market, for example, the OPC UA TSN protocol controls
North America, the Largest Revenue Producer in Public Safety and Security Market
North America, the Largest Revenue Producer in Public Safety and Security Market
The size of the public safety and security market was at $411 billion in the year 2021, which will reach over $1,115 billion by the year 2030, advancing at a growth rate of around 12% in the years to come. This is largely ascribed to the rising application of innovative technologies in smart cities, increasing crime rates, the increasing cases of disastrous accidents, and the growing count of terrorist activities

All 5 Releases


More Releases for Myasthenia

Myasthenia Gravis Market | Rising Prevalence Of Neuromuscular Disorders
According to Precision Business Insights (PBI), the latest report, the Myasthenia Gravis market is expected to be valued at USD 1,734.6 million in 2022, growing at an 8.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global Myasthenia Gravis market increasing prevalence of neuromuscular disorders, and rising awareness about effective treatment. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/myasthenia-gravis-market/ Medication Segment to Dominate the Myasthenia
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles. Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report with TOC
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report with TOC
Global Myasthenia Gravis Industry Analysis By Geography
Stratistics MRC's Myasthenia Gravis Market report explains company profiling, key segments, market trends, top players and regional, country-level segments. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report with TOC @
Global Myasthenia Gravis Industry Report Top 5 Players
Stratistics MRCs 2021 Myasthenia Gravis Market Report Key players include - Medtronic Plc., Novartis AG, Koninklijke Philips N.V., Pfizer Inc., Baxter International. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report